Novartis on Tuesday announced that it is investing in biotherapeutics with the creation of a fully integrated, dedicated USD 300 million scientific environment that will enhance its capacity and capabilities for early technical development of biologics.
According to the company’s press statement, the multi-year investment will be implemented across existing Novartis locations in Switzerland, Slovenia and Austria and it focus on both drug substance and drug product development. According to the company, this move will strengthen Novartis’ ability to deliver on the increasing growth and diversity of its early-stage biotherapeutics portfolio.
“Across the industry, biotherapeutics account for almost one-half of all recent new drug approvals and have enormous potential to address unmet need across a wide range of diseases. We are building the scientific environment necessary to bring these complex biologic compounds from the bench through development in an integrated, seamless, and rapid fashion. In doing so, we are supporting our broader ambition to enable faster development and focused prioritization across our global portfolio,” said Reto Fischer, head of technical research division, global drug development (GDD), Novartis in a statement.
The company claims that Novartis’ early-stage biologics portfolio has grown significantly in the last 15 years. It has also expanded beyond conventional monoclonal antibodies into a wide range of novel development candidates with potential to be first-in-class, best-in-class, or both, including antibody-drug conjugates and therapeutic proteins, it stated.
“This investment is intended to position Novartis at the forefront of biotherapeutic development, by supporting the company’s increasingly sophisticated pipeline with the most advanced technical infrastructure, alongside the highest level of capabilities. It will create seamless, end-to-end development and manufacturing environments by embedding biologics development within existing Novartis commercial manufacturing facilities in Slovenia and Austria as well as by establishing a biologic’s hub on the Basel St. Johann Campus in Switzerland alongside the NIBR biologics centre fostering scientific innovation, technology leadership and talent attraction. Collectively these commitments will enhance development processes targeting faster transition times from pre-clinical to first in human studies,” the company stated on Monday.
The pharma major announced that the investment will: Strengthen the Novartis St. Johann campus in Basel by investing USD 100 million to establish a biologics hub to complement the existing NIBR Biologics Centre; Create a biocampus in Mengeš, Slovenia with an investment of USD 110 million in clinical manufacturing capabilities (non cGMP and cGMP) and technical development capabilities in proximity of development operations; and Amplify synergies and strategic proximity at the Schaftenau campus in Austria with a USD 60 million investment in development manufacturing capacity and capabilities.
“The science of developing biologics is increasingly sophisticated, and we are excited to meet its challenges head-on. We look forward to amplifying the knowledge and experience of our associates to ensure that biologics development is an exhilarating and rewarding process for our current and future colleagues – and that is ultimately a source of profoundly innovative new therapies for patients worldwide,” Jonathan Novak, global head for biologics, technical research division, GDD at Novartis stated on Monday.